MedTrace Logo

PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28

NCT00407693 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2019-11-19

No results posted yet for this study

Summary

In this study we will examine where the radioactive tracer \[11C\]PBR28 is distributed in the body of healthy volunteers to calculate the radiation exposure to organs of the body. We will also test if \[11C\]PBR28 binds to your blood cells and compare with the binding in PET images.

Conditions

  • Healthy

Interventions

DRUG

[C-11]PRB28

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Masahiro Fujita, M.D. · National Institute of Mental Health (NIMH)

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-28
Completion
2016-07-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407693 on ClinicalTrials.gov